肝外胆管癌和胆囊癌术后辅助放疗与未放疗疗效比较的<i>Meta分析</i>

doi:10.3760/cma.j.issn.1004-4221.2019.11.008

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的采用Meta分析方法比较肝外胆管癌和胆囊癌术后辅助放疗与未放疗间的疗效差异。方法计算机检索PubMed、EMbase、Cochrane图书馆、万方、维普、CNKI及中国生物医学等数据库,搜集有关肝外胆管癌和胆囊癌术后辅助放疗与未放疗比较的临床对照研究资料,汇总数据采用RevMan5.3和Stata14.0软件进行分析。两组间差异采用OR及 95%CI描述。结果最终纳入20个包括 1258例患者的临床对照研究资料。Meta分析结果显示,与肝外胆管癌和胆囊癌术后未行放疗相比,辅助放疗组 5年生存率更高(OR=1.67,95%CI为 1.29~2.18,P=0.001)。术后辅助放疗能明显提高切缘阳性(OR=3.43,95%CI为 1.56~7.75,P=0.002)以及淋巴结阳性(OR=7.44;95%CI为1.24~44.72,P=0.03)患者的 5年生存率。此外,术后辅助放疗组的局部复发率更低(OR=0.56,95%CI为 0.39~0.80,P=0.01),但远处转移率两组相似(OR=1.22,95%CI为 0.86~1.73,P=0.270)。放疗所致≥3级急性毒性及慢性毒性反应发生率分别为 0~11.9%和 0~21.7%。结论与肝外胆管癌和胆囊癌术后未行放疗相比,术后辅助放疗是有效且安全的治疗方法。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	任毕欣
	刘磊
	杨咏强
	郭旗
	张力元
	田野

关键词 ：肝外胆管癌/放射疗法, 胆囊癌/放射疗法, 辅助治疗, 荟萃分析

Abstract：Objective To compare the efficacy of postoperative adjuvant radiotherapy and non-radiotherapy in patients with extrahepatic cholangiocarcinoma and gallbladder carcinoma by a meta-analysis. Methods The controlled clinical trials of postoperative adjuvant radiotherapy versus non-radiotherapy of extrahepatic cholangiocarcinoma and gallbladder carcinoma were searched from PubMed, EMbase, Cochrane Library, Wanfang database, CNKI, Chongqing VIP and CBM databases. The obtained data were analyzed using RevMan 5.3 and Stata 14.0 statistical software. The difference between two groups was estimated by calculating the odds ratio (OR) with 95% confidence interval (CI). Results A total of 20 controlled clinical trials involving 1258 extrahepatic cholangiocarcinoma and gallbladder carcinoma patients were included in this meta-analysis. The meta-analysis demonstrated that the 5-year survival rate in the adjuvant radiotherapy group was significantly higher than that in the non-radiotherapy group (OR=1.67, 95%CI:1.29-2.18, P=0.001). The 5-year survival rates in those with lymph node positive disease (OR=7.44, 95%CI:1.24-44.72, P=0.03) and positive margins disease (OR=3.43,95%CI:1.56-7.75,P=0.002) were significantly enhanced by postoperative adjuvant radiotherapy. The local recurrence rate in the adjuvant radiotherapy group was significantly lower than that in the non-radiotherapy group (OR=0.56,95%CI:0.39-0.80,P=0.01), whereas the distant metastasis rate did not significantly differ between two groups (OR=1.22,95%CI:0.86-1.73,P=0.27). The incidence rates of acute toxicity and chronic toxicity of grade ≥3 caused by radiotherapy were 0-11.9% and 0-21.7%,respectively. Conclusion Compared with non-radiotherapy, postoperative adjuvant radiotherapy is a safer and more effective postoperative treatment for extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Key words： Extrahepatic cholangiocarcinoma/radiotherapy Gallbladder carcinoma/radiotherapy Adjuvant therapy Meta-analysis

收稿日期: 2019-01-21

基金资助:江苏省社会发展-临床前沿技术(BE2018657);江苏省医学创新团队A类(CXDT-37);苏州市临床医学中心建设项目(Szzxj201503);姑苏卫生领军人才(62)

通讯作者: 田野,Email:dryetian@126.com

引用本文:

任毕欣,刘磊,杨咏强等. 肝外胆管癌和胆囊癌术后辅助放疗与未放疗疗效比较的Meta分析[J]. 中华放射肿瘤学杂志, 2019, 28(11): 836-839.

Ren Bixin,Liu lei,Yang Yongqiang et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy and non-radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(11): 836-839.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2019.11.008 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2019/V28/I11/836

[1] Borghero Y,Crane CH,Szklaruk J,et al. Extrahepatic bile duct adenocarcinoma:patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone[J]. Ann Surg Oncol,2008,15(11):3147-3156. DOI:10.1245/s10434-008-9998-7.
[2] Cheng Q,Luo X,Zhang B,et al. Predictive factors for prognosis of hilar cholangiocarcinoma:Postresection radiotherapy improves survival[J]. Eur J Surg Oncol,2007,33(2):202-207. DOI:10.1016/j.ejso.2006.09.033.
[3] Gerhards MF,van Gulik TM,González D,et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma[J]. World J Surg,2003,27(2):173-179. DOI:10.1007/s00268-002-6434-1.
[4] Gold DG,Miller RC,Haddock MG,et al. Adjuvant therapy for gallbladder carcinoma:the mayo clinic experience[J]. Int J Radiat Oncol Biol Phys,2009,75(1):150-155. DOI:10.1016/j.ijrobp.2008.10.052.
[5] Gu B,Qian L,Yu H,et al. Concurrent chemoradiotherapy in curatively resected gallbladder carcinoma:a propensity score-matched analysis[J]. Int J Radiat Oncol Biol Phys,2018,100(1):138-145. DOI:10.1016/j.ijrobp.2017.09.029.
[6] Heron DE,Stein DE,Eschelman DJ,et al. Cholangiocarcinoma:the impact of tumor location and treatment strategy on outcome[J]. Am J Clin Oncol,2003,26(4):422-428. DOI:10.1097/01. COC.0000026833.73428.1F.
[7] Hughes MA,Frassica DA,Yeo CJ,et al. Adjuvant concurrent chemoradation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys,2007,68(1):178-182. DOI:10.1016/j.ijrobp.2006.11.048.
[8] Im JH,Seong J,Lee IJ,et al. Surgery alone versus surgery followed by chemotherapy and radiotherapy in resected extrahepatic bile duct cancer:treatment outcome analysis of 336 patients[J]. Cancer Res Treat,2016,48(2):583-595. DOI:10.4143/crt.2015.091.
[9] Itoh H,Nishijima K,Kurosaka Y,et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder[J]. Dig Dis Sci,2005,50(12):2231-2242. DOI:10.1007/s10620-005-3040-8.
[10] Lindell G,Holmin T,Ewers SB,et al. Extended operation with or without intraoperative (IORT) and external (EBRT) radiotherapy for gallbladder carcinoma[J]. Hepatogastroenterology,2003,50(2):310-314.
[11] Pitt HA,Nakeeb A,Abrams RA,et al. Perihilar cholangiocarcinoma:postoperative radiotherapy does not improve survival[J]. Ann Surg,1995,221(6):788-798.
[12] Sagawa N,Kondo S,Morikawa T,et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma[J]. Surg Today,2005,35(3):548-552. DOI:10.1007/s00595-005-2989-4.
[13] Todoroki T,Kawamoto T,Otsuka M,et al. Benefits of combining radiotherapy with aggressive resection for stage Ⅳ gallbladder cancer[J]. Hepatogastroenterology,1999,46(10):1585-1591.
[14] Todoroki T,Ohara K,Kawamoto T,et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma[J]. Int J Radiat Oncol Biol Phys,2000,46(3):581-587.
[15] Wang J,Narang AK,Sugar EA,et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma:a multi-institutional experience[J]. Ann Surg Oncol,2015,Suppl 3:S1100-1106. DOI:10.1245/s10434-015-4685-y.
[16] Zlotecki RA,Jung LA,Vauthey JN,et al. Carcinoma of the extrahepatic biliary tract:Surgery and radiotherapy for curative and palliative intent[J]. Radiat Oncol Invest,1998,6(2):240-247. DOI:10.1002/(SICI)1520-6823(1998)6:5<240::AID-ROI6>3.0. CO;2-R.
[17] 冯世杰,万百顺,贺涛,等. 胆囊癌根治术后辅助放疗对患者预后的影响[J]. 胃肠病学和肝病学杂志,2018,27(6):703-705. DOI:10.3969/ j.issn.1006-5709.2018.06.024.
Feng SJ,Wu BS,He T,et al. Prognostic impact of adjuvant radiotherapy after radical cholecystectomy[J]. J Gastroerol Hepatol,2018(6):240-247. DOI:10.3969/ j.issn.1006-5709.2018.06.024.
[18] 孟岩,肖作平,张柏和,等. 局部晚期肝门部胆管癌根治术后放疗的价值[J]. 中华放射肿瘤学杂志,2006,15(2):114-116. DOI:10.3760/j.issn.1004-4221.2006.02.010.
Meng Y,Xiao ZP,Zhang BH,et al. The value of post-operative radiotherapy for locally advanced hilar cholangiocarcinoma[J]. Chin J Radiat Oncol,2006,15(2):114-116. DOI:10.3760/j.issn.1004-4221.2006.02.010.
[19] 梁建伟,王征,周志祥,等. 胆囊癌术后辅助治疗的价值[J]. 中华普通外科杂志,2012,27(6):445-448. DOI:10.3760/cma.j.im.1007-631X.2012.06.003.
Liang JW,Wang Z,Zhou ZX,et al. Value of adjuvant therapy after gallbladder cancer surgery[J]. Chin J General Surg,2012,27(6):445-448. DOI:10.3760/cma.j.im.1007-631X.2012.06.003.
[20] 饶石磊,王旸,贾彦召,等. 肝门部胆管癌临床诊断与放疗疗效分析[J]. 中国卫生产业,2014,24(2):135-136.
Rao SL,Wang Y,Jia YZ,et al. Clinical diagnosis and radiotherapy efficacy analysis of hilar cholangiocarcinoma[J]. Chin Health Industry,2014,24(2):135-136.
[21] Ben-Josef E,Guthrie KA,El-Khoueiry AB,et al. SWOG S0809:a phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol,2015,33(24):2617-2622. DOI:10.1200/JCO.2014.60.2219.
[22] Shinohara ET,Mitra N,Guo M,et al. Radiotherapy is associated with improved survival inadjuvant and palliative treatment of extrahepatic cholangiocarcinomas[J]. Int J Radiat Oncol Biol Phys,2009,74(4):1191-1198. DOI:10.1016/j.ijrobp.2008.09.017.
[23] Wang SJ,Lemieux A,Kalpathy-Cramer J,et al. Nomogram forpredicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer[J]. J Clin Oncol 2011,29(35):4627-4632. DOI:10.1200/JCO.2010.33.8020.
[24] Tran-Cao HS,Zhang Q,Sada YH,et al. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts[J]. Cancer,2018,124(1):74-83. DOI:10.1002/cncr.30968.
[25] Leng KM,Liu YP,Wang ZD,et al. Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection[J]. Onco Targets Ther,2017,10(6):2257-2266. DOI:10.2147/OTT. S131873.
[26] Glazer ES,Liu P,Abdalla EK,et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins[J]. J Gastrointest Surg,2012,16(9):1666-1671. DOI:10.1007/s11605-012-1935-1.
[27] Horgan AM,Amir E,Walter T,et al. Adjuvant therapy in the treatment of biliary tract:cancer:a systematic review and meta-analysis[J]. J Clin Oncol,2012,30(16):1934-1940. DOI:10.1200/JCO.2011.40.538.
[28] Beltrán MB,Allal AS,Gich I,et al. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies[J]. Cancer Treat Rev,2012,38(2):111-119. DOI:10.1016/j.ctrv.2011.05.00.
[29] Kim BH,Kwon J,Chie EK. Adjuvant chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma:a systematic review and Meta-analysis[J]. Ann Surg Oncol,2018,25(1):255-264. DOI:10.1245/s10434-017-6139-1.
[30] National comprehensive cancer network. Clinical practice guidelines in oncology. Hepatobiliary cancers,version 1.2019[DB/OL][2019-01-10].https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.